Targeted Oncology3d
Low-Dose Pembrolizumab Shows Promise vs Standard Dose in Stage IV NSCLC
A study found that reducing the dose of pembrolizumab in patients with advanced stage non–small cell lung cancer did not ...
Medscape10d
Perioperative Pembrolizumab Continues to Show Benefit in NSCLC
The event-free survival benefit with perioperative pembrolizumab in early NSCLC depends on the post-neoadjuvant residual ...
ThePrint on MSN22h
This experimental lung cancer drug outperforms blockbuster medicine Keytruda. But there’s a catch
In head-to-head clinical trial, Chinese firm Akeso’s ivonescimab beat top-selling drug pembrolizumab sold as Keytruda by ...
Ivonescimab outperforms pembrolizumab in study for first-line treatment of PD-L1-positive advanced NSCLC: Clinical trial
Data from a Phase 3 study has revealed that ivonescimab demonstrates a statistically significant and clinically meaningful ...
pulmonologyadvisor11d
HARMONi-2: Ivonescimab Outperforms Pembrolizumab in Advanced NSCLC
Ivonescimab improved PFS when compared to pembrolizumab as first-line therapy in patients with advanced NSCLC in the phase 3 HARMONi-2 trial.
Adjuvant durvalumab extends survival in small cell lung cancer
For patients with limited-stage small cell lung cancer, adjuvant therapy with durvalumab leads to significantly longer ...
Merck's Keytruda Secures First FDA-Approval For Rare Form Aggressive Cancer
The FDA has approved Merck's Keytruda (pembrolizumab) in combination with pemetrexed and platinum chemotherapy for first-line ...
Merck/Daiichi Sankyo Partnered Lung Cancer Candidate Meets Primary Goal In Late-Stage Study
Merck reported topline data from its HERTHENA-Lung02 phase 3 trial of patritumab deruxtecan in EGFR-mutated non-small cell ...
Cure Today9d
A New Era in Small Cell Lung Cancer Treatment
Dr. Debu Tripathy, editor-in-chief of CURE magazine, discusses the advancements made in small cell lung cancer.
Summit stock soars as lung cancer drug beats Merck’s Keytruda in late-stage trial
Summit Therapeutics stock rises 51% as ivonescimab shows promising results in lung cancer trial compared to Keytruda.